Mosaiques diagnostics provides highly innovative Clinical Proteomics services for academic institutions and pharmaceutical companies. Mosaiques revolutionary CE-MS technology (capillary electrophoresis coupled to mass spectrometry) helps to diagnose severe diseases at an early development stage.
Precise and reliable detection of diseases in early stages allows prompt initiation of therapy and results in minimizing patients' burden
Explore our offer here
Mosaiques Diagnostics nominated for Innovationspreis Niedersachsen 2018.
Link to full article here.
Mosaiques Diagnostics GmbH at the Awards ceremony for the "Innovationspreis Niedersachsen 2018".
"Family’s grief sparks a quest for better bladder cancer cures"
Read the full article here.
Der Erfinder der Proteomanalyse, Prof. Mischak, als „Lecturer of the Year 2018“ vom Belgischen Hypertensie Comité benannt
Führende deutsche Wissenschafts-Institute des „Forum Gesundheitsforschung“ beim BMBF fordern für die dringend benötigte Präzisionsmedizin die klinische Proteomanalyse! Die Wissenschafts-Institute des „Forum Gesundheitsforschung“ sind:
Wissenschaftsrat ● Deutsche Forschungsgemeinschaft ● Helmholtz-Gemeinschaft ● Max-Planck-Gesellschaft ● Leibniz-Gemeinschaft ● Fraunhofer Gesellschaft ● Medizinischer Fakultätentag ● Verband der Universitätsklinika Deutschland ● Deutsche Zentren der Gesundheitsforschung ● Vertreterinnen und Vertreter aus der Wirtschaft
The mosaiques diagnostics & therapeutics AG was established in Hannover (Germany).
The company’s core competence is the early and reliable detection of diseases enabling personalized medicine during therapy and drug development. The company utilizes diagnostic polypeptide patterns (DiaPat) derived from the fast and accurate analysis of proteins and polypeptides in body fluids (e.g. urine, bile and cerebrospinal fluid).
